Lactobacillus as a Therapeutic Agent: A Comprehensive Clinical and Microbiological Review

Section 1: The Lactobacillus Genus: Foundational Biology and Evolving Taxonomy

This section establishes the fundamental biological identity of [Lactobacillus] and addresses the recent, significant shift in its taxonomy, a crucial framework for interpreting the scientific and clinical research discussed in this report.

1.1 Core Biological and Metabolic Characteristics

[Lactobacillus] is a genus of Gram-positive, rod-shaped, non-spore-forming bacteria belonging to the phylum Firmicutes.[1] They are typically catalase-negative, facultatively anaerobic or microaerophilic, meaning they can thrive in environments with little to no oxygen.[1] A key characteristic is their high tolerance for acidic conditions, which is fundamental to their role in fermented foods and their ability to survive transit through the low pH environment of the human stomach to reach the intestines.[3]

The defining feature of the genus is its metabolism of carbohydrates to produce lactic acid, making it the largest and most prominent group within the Lactic Acid Bacteria (LAB).[1] Based on their metabolic pathways and end-products, lactobacilli are traditionally divided into three functional groups [1]:

• Obligate Homofermentative: These species utilize the glycolysis pathway to ferment hexose sugars (like glucose) almost exclusively into lactic acid. This efficient acid production is a key trait for strains used in applications requiring rapid acidification. Examples include [Lactobacillus acidophilus] and [Lactobacillus salivarius].[1]
• Facultative Heterofermentative: These species primarily produce lactic acid from hexoses. However, under certain conditions, such as the presence of pentose sugars or limited glucose, they can switch to the phosphoketolase pathway to produce a mix of lactic acid, ethanol or acetic acid, and carbon dioxide (CO2​). This metabolic flexibility is seen in species like [Lactobacillus casei] and [Lactobacillus plantarum].[1]
• Obligate Heterofermentative: These species always utilize the phosphoketolase pathway to ferment hexoses, consistently producing a mixture of lactic acid, ethanol/acetic acid, and CO2​. This production of multiple metabolites, including gas, has direct clinical implications. Examples include [Lactobacillus reuteri] and [Lactobacillus fermentum].[1]

The genomic landscape of lactobacilli is remarkably diverse. Genome sizes range from 1.2 to 4.9 megabases (Mb), encoding anywhere from approximately 1,200 to 4,800 protein-coding genes.[2] This genomic plasticity, which includes a wealth of mobile genetic elements like plasmids and microsatellites, provides the molecular foundation for the vast functional differences observed not only between species but, critically, between individual strains.[2]

1.2 A Genus in Flux: The 2020 Taxonomic Reclassification

The traditional classification of [Lactobacillus] encompassed over 250 species, creating a highly heterogeneous and phylogenetically inconsistent group. To resolve this, a major taxonomic revision was undertaken in 2020, leveraging modern genomic data to split the overarching genus into the emended, more narrowly defined [Lactobacillus] genus and 23 novel genera.[2] The redefined

[Lactobacillus] genus now contains only 44 species that are specifically adapted to vertebrate or insect hosts.[2]

This reclassification is not a mere academic exercise; it represents a fundamental paradigm shift with direct implications for clinical practice and research synthesis. Without an understanding of this new framework, clinicians and researchers risk misinterpreting the body of evidence, potentially conflating studies on phylogenetically distinct organisms or failing to recognize the continuity of research on newly reclassified species. Much of the historical literature uses the old nomenclature, making a "translation key" essential for accurate evidence appraisal.

---

Table 1.1: Mapping of Key Lactobacillus Species to New 2020 Nomenclature

Historical Name	New Genus Name	Full New Species Name	Key Examples of Studied Strains
Lactobacillus acidophilus	Lactobacillus	Lactobacillus acidophilus	NCFM, DDS-1, LA-05, ATCC 4356 7
Lactobacillus casei	Lacticaseibacillus	Lacticaseibacillus casei	Shirota (YIT9029), DN114001 3
Lactobacillus plantarum	Lactiplantibacillus	Lactiplantibacillus plantarum	299v, PS128, IS-10506 5
Lactobacillus rhamnosus	Lacticaseibacillus	Lacticaseibacillus rhamnosus	GG (ATCC 53103), GR-1 3
Lactobacillus reuteri	Limosilactobacillus	Limosilactobacillus reuteri	DSM 17938, RC-14, ATCC 55730 11
Lactobacillus fermentum	Limosilactobacillus	Limosilactobacillus fermentum	VRI-033 PCC 14
Lactobacillus salivarius	Ligilactobacillus	Ligilactobacillus salivarius	N/A (as per sources) 1
Lactobacillus crispatus	Lactobacillus	Lactobacillus crispatus	M247 17
Lactobacillus gasseri	Lactobacillus	Lactobacillus gasseri	SBT2055 19
Lactobacillus delbrueckii	Lactobacillus	Lactobacillus delbrueckii	subsp. bulgaricus 3

---

1.3 Natural Role in the Human Microbiota

[Lactobacillus] species are integral commensal organisms within the human superorganism, forming a mutualistic relationship with their host.[1] They are prominent members of the microbiota at numerous body sites, most notably the gastrointestinal (GI) tract, from the oral cavity to the colon, and the female genitourinary tract.[1] In these ecosystems, they form biofilms that allow them to persist and maintain stable populations.[2]

This relationship is symbiotic. The host provides a nutrient-rich and stable environment, and in return, lactobacilli offer significant benefits. They assist in the digestion of complex dietary substrates, produce essential metabolites like vitamins and short-chain fatty acids, and provide a critical defense mechanism known as "colonization resistance," which helps protect the host from invading pathogens.[1] The indigenous (autochthonous)

[Lactobacillus] flora, which includes species like [Lactobacillus gasseri] and [Limosilactobacillus reuteri], is typically established early in life and can remain stable for a lifetime, though it can be temporarily influenced by transient (allochthonous) species consumed in food.[19]

Section 2: The Cornerstone of Probiotic Science: The Imperative of Strain Specificity

To understand and effectively apply [Lactobacillus] as a therapeutic agent, one concept is paramount: biological activity and health benefits are properties of specific strains, not the entire genus or even the species. A failure to appreciate this principle of strain specificity is the primary source of inconsistent clinical trial results, consumer confusion, and failed therapeutic applications.

2.1 Beyond Genus and Species: The Strain as the Functional Unit

The effects of probiotics are highly strain-specific, a point consistently reinforced across the scientific literature.[9] This means that the findings from a clinical trial on one specific strain cannot be extrapolated to another, even if they belong to the same species.[10] Just as all dogs are the same species (

[Canis lupus familiaris]) but a Chihuahua and a Great Dane possess vastly different physical and behavioral traits, strains within a single [Lactobacillus] species can exhibit dramatically different, and in some cases, opposing, physiological effects.[11]

A stark illustration of this principle comes from research on Irritable Bowel Syndrome (IBS). [Lactiplantibacillus plantarum] strain 299v has been shown in multiple clinical trials to be effective in reducing symptoms like pain and bloating.[5] In contrast, a different strain,

[L. plantarum] MF1298, was found to actually worsen IBS symptoms in a clinical study.[10] This unequivocally demonstrates that one cannot simply prescribe "

[L. plantarum]" for IBS; the specific strain designation (e.g., 299v) is the true active ingredient.

This principle of strain specificity necessitates a re-evaluation of how probiotics are regulated, marketed, and prescribed. The common practice of marketing products based on species-level identification (e.g., "[Lactobacillus acidophilus]") is scientifically insufficient, as it implies a generalized benefit that may be exclusive to a single, often unstated, strain.[10] For probiotics to be regarded as legitimate therapeutic agents, they must be held to the same standard of specificity as pharmaceuticals, where the exact active molecule (the strain) is identified and its dose is precisely quantified.

2.2 Genomic Basis of Strain-Specific Actions

The molecular basis for strain specificity lies in the high variability of [Lactobacillus] genomes.[2] Even closely related strains within the same species can differ significantly in their genetic content. These differences can include their portfolio of plasmids, the composition of surface proteins that mediate adhesion, their enzymatic capabilities for metabolizing substrates, and the presence or absence of genes required to produce specific bioactive compounds like bacteriocins or exopolysaccharides (EPS).[2]

Advanced molecular typing methods can reveal these differences. Techniques like pulsed-field gel electrophoresis (PFGE) and repetitive DNA element-based PCR (rep-PCR) can generate unique genetic "fingerprints" for each strain, distinguishing between organisms that may appear identical using traditional phenotypic methods.[23] More sophisticated techniques, such as subtractive hybridization, have even been used to isolate DNA sequences that are entirely unique to a single probiotic strain (e.g.,

[Lacticaseibacillus rhamnosus] 35), enabling the development of highly specific PCR-based tests to confirm its identity and presence.[23] This genetic uniqueness is the direct cause of functional uniqueness.

Furthermore, the evidence also points to disease-specificity, meaning a strain effective for one condition may be useless for another.[9] For example, the multi-strain preparation Lab4 appears effective for managing IBS but is ineffective in preventing antibiotic-associated diarrhea.[10] This suggests that the mechanisms required for these conditions are distinct. AAD prevention may rely heavily on rapid growth and competitive exclusion to fill the niche cleared by antibiotics, whereas IBS treatment may require more nuanced immunomodulatory or neuro-modulatory actions. A given strain may possess the molecular tools for one task but not the other. This reality challenges the "more strains are better" marketing narrative often used for multi-strain products, unless that specific combination has been clinically validated for a specific outcome. There is no "universal" probiotic; there are only optimal strains for specific clinical contexts.

Section 3: Multifaceted Mechanisms of Probiotic Action

[Lactobacillus] strains interact with the host through a complex and synergistic array of mechanisms to confer health benefits. These actions are not mutually exclusive and often work in concert, ranging from direct competition with pathogens in the gut lumen to sophisticated signaling dialogues with the host immune system. For any of these mechanisms to be effective, a probiotic must first possess the intrinsic ability to survive transit through the acidic stomach and bile-rich small intestine.[3]

3.1 Luminal and Mucosal Actions: Barrier Enhancement and Competitive Exclusion

A primary function of probiotics is to reinforce the natural defenses of the gut barrier. This occurs through several mechanisms:

• Competition for Adhesion: Lactobacilli physically compete with pathogenic bacteria for limited binding sites on the surface of intestinal epithelial cells (IECs) and on glycoproteins within the protective mucus layer.[1] By occupying these sites, they prevent pathogens from gaining a foothold, a key aspect of colonization resistance.
• Surface-Level Effectors: This crucial adhesion is not random; it is mediated by specific structures on the bacterial surface [1]:
• S-layer (Surface Layer) Proteins: Found in strains like [L. acidophilus] ATCC 4356, the S-layer is a crystalline, self-assembling layer of proteins that forms the outermost cell surface. It can facilitate adhesion to host cells and has been shown to exert direct anti-viral activity by blocking pathogen attachment to host receptors.[1]
• Pili (Fimbriae): These are long, hair-like protein appendages that protrude from the bacterial cell. The SpaC pili of [Lacticaseibacillus rhamnosus] GG (LGG), for instance, are critical for its strong, specific adhesion to the intestinal epithelium and have been demonstrated to out-compete pathogens for binding.[1]
• Gut Barrier Fortification: Beyond simple competition, probiotic strains can actively strengthen the integrity of the intestinal barrier. Strains of [Limosilactobacillus reuteri] have been shown to increase the expression of mucin genes (MUC2 and MUC13), leading to the secretion of a thicker, more robust mucus layer that physically separates luminal bacteria from the underlying epithelium.[26] Similarly, the well-studied VSL#3 formulation induces mucin production.[27] Furthermore, specific probiotic components, such as the secreted p40 and p75 proteins from LGG, have been shown to preserve the function of tight junctions—the protein complexes that seal the gaps between epithelial cells. By maintaining these junctions, probiotics help prevent intestinal hyperpermeability, or "leaky gut," which limits the translocation of inflammatory molecules from the gut into the bloodstream.[22]

3.2 Immunomodulation: A Dialogue with the Host Immune System

Lactobacilli engage in a sophisticated dialogue with the host's vast mucosal immune system, demonstrating a remarkable ability to modulate immune responses in a context-dependent manner.[24]

• Cytokine Regulation: A key mechanism of action is the regulation of cytokine production. Many therapeutic strains, including [L. acidophilus] and [L. reuteri], can shift the immune balance away from a pro-inflammatory state. They achieve this by downregulating the production of pro-inflammatory cytokines such as Tumor Necrosis Factor-alpha (TNF-α) and Interleukin-6 (IL-6), while simultaneously promoting the secretion of anti-inflammatory cytokines like Interleukin-10 (IL-10).[7] This rebalancing is central to their beneficial effects in inflammatory conditions like IBD and IBS. For example, in a trial involving IBS patients, the probiotic [Bifidobacterium infantis] 35624 normalized the ratio of pro-inflammatory IL-12 to anti-inflammatory IL-10, correlating with clinical improvement.[27]
• Toll-Like Receptor (TLR) Interaction: Bacterial components, including lipoteichoic acids (LTAs) from the cell wall and unmethylated CpG motifs in bacterial DNA, are recognized by pattern recognition receptors on host cells, most notably Toll-like receptors (TLRs) such as TLR2, TLR4, and TLR9.[7] This interaction triggers intracellular signaling cascades that profoundly shape the subsequent immune response. The outcome—whether pro- or anti-inflammatory—is highly dependent on the specific bacterial component, the strain it comes from, and the type of host cell it interacts with.
• Enhancing Humoral Immunity: Probiotics can bolster mucosal defenses by stimulating the production of secretory Immunoglobulin A (sIgA), the most abundant antibody in the mucosal immune system and the first line of defense against toxins and pathogens.[7] LGG, for instance, has been shown to enhance IgA secretion, which helps to trap and neutralize pathogens within the gut lumen before they can cause infection.[22]

3.3 Production of Bioactive Metabolites

The metabolic byproducts generated by [Lactobacillus] during fermentation are not merely waste; they are potent bioactive molecules that are central to their probiotic effects.[4]

• Organic Acids: The production of lactic acid and acetic acid is a hallmark of LAB. These acids lower the pH of the local environment, creating conditions that are inhospitable to the growth of many acid-sensitive pathogens like [Salmonella] and [E. coli].[1]
• Short-Chain Fatty Acids (SCFAs): Metabolites such as acetate, propionate, and butyrate, produced primarily by heterofermentative strains, are crucial signaling molecules. They serve as the primary energy source for the cells lining the colon (colonocytes), and they also regulate immune function, influence gut motility, and can even impact systemic health by modulating appetite-regulating hormones.[20]
• Bacteriocins: Certain strains of [Lactobacillus] synthesize and secrete bacteriocins, which are small, antimicrobial peptides. These molecules can directly kill or inhibit the growth of closely related bacterial species, including pathogens, giving the probiotic strain a competitive advantage in the gut ecosystem.[3]
• Reuterin (3-HPA): Produced specifically by certain strains of [Limosilactobacillus reuteri] during the metabolism of glycerol, reuterin (3-hydroxypropionaldehyde) is a powerful, broad-spectrum antimicrobial compound. It is effective against a wide range of microorganisms, including pathogenic bacteria, fungi, and protozoa.[12]
• Neurotransmitters: Demonstrating a direct link to the gut-brain axis, some LAB strains have the genetic machinery to produce neuroactive compounds. Notably, certain lactobacilli can synthesize γ-Aminobutyric Acid (GABA), the primary inhibitory neurotransmitter in the mammalian central nervous system, from glutamate.[30]

The discovery that isolated bacterial components, such as the p40 protein from LGG or its extracellular vesicles, can replicate the therapeutic effects of the live organism marks a significant evolution in the field.[22] This opens a potential avenue for the development of "postbiotics" or "pharmabiotics"—purified, stable bacterial molecules that could offer the benefits of probiotics with enhanced safety and standardization. This approach would be particularly advantageous for use in vulnerable, immunocompromised populations where the administration of live microorganisms carries inherent risks.

Section 4: Evidence-Based Review of Clinical Applications

This section critically appraises the clinical evidence for [Lactobacillus] across key health domains, focusing on the quality of evidence from meta-analyses, Cochrane reviews, and randomized controlled trials (RCTs), while emphasizing the specific strains and dosages associated with therapeutic effects. The strength of evidence varies dramatically by indication, ranging from robust and practice-changing to inconclusive and conflicting.

4.1 Gastrointestinal Disorders

• Antibiotic-Associated Diarrhea (AAD): This is one of the most well-established and strongly supported indications for probiotic use. Multiple high-quality meta-analyses and Cochrane reviews have consistently concluded that the prophylactic administration of specific [Lactobacillus] strains significantly reduces the risk of developing AAD in both adult and pediatric populations receiving antibiotics.[31] The data indicates that probiotics can lower the incidence of AAD from approximately 19% in control groups to around 8% in treatment groups.[36] One pooled analysis in adults demonstrated a 37% relative risk reduction.[31] The effect appears to be dose-dependent, with higher doses (typically above 5–10 billion Colony-Forming Units, or CFUs, per day) showing greater protective effects.[31] The strains with the most substantial body of evidence are [Lacticaseibacillus rhamnosus] GG (LGG) and the probiotic yeast [Saccharomyces boulardii].[36] It is crucial that the probiotic is administered concurrently with the antibiotic therapy (though separated by at least two hours to ensure viability) to be effective.[38]
• Irritable Bowel Syndrome (IBS): There is a moderate but consistently growing body of evidence supporting the use of probiotics for improving global IBS symptoms, especially bloating, flatulence, and abdominal pain.[27] This is biologically plausible, as individuals with IBS often exhibit altered gut microbiota with lower relative abundance of native lactobacilli and bifidobacteria.[27] The proposed mechanisms are multifaceted, involving modulation of the gut-brain axis, reduction of visceral hypersensitivity (the heightened pain perception common in IBS), improvement of gut motility, and local anti-inflammatory effects.[27] For instance, [L. acidophilus] has been shown to upregulate opioid and cannabinoid receptors in colonic cells, which may directly blunt pain signals.[27] High-dose, multi-strain formulations appear to be most effective. The VSL#3 formulation (now sold as Visbiome) and Symprove, both containing multiple [Lactobacillus] species, are supported by strong clinical trial data.[27] Among single strains, [Lactiplantibacillus plantarum] 299v has robust evidence for efficacy.[10] A key clinical nuance is that benefits often require several weeks of consistent use to manifest and may dissipate upon discontinuation, suggesting that ongoing supplementation is likely necessary for managing this chronic condition.[40]
• Helicobacter pylori Infection: [Lactobacillus] is not effective as a standalone cure for [H. pylori] infection. However, strong evidence shows that it is a valuable adjunct to standard triple- or quadruple-antibiotic therapy. When taken alongside the antibiotic regimen, specific [Lactobacillus] strains can increase the pathogen eradication rate while significantly reducing the incidence and severity of common treatment-related side effects, such as diarrhea, nausea, and taste disturbances.[7]

4.2 Vaginal Health

A healthy vaginal microbiome is typically characterized by the dominance of [Lactobacillus] species, which produce lactic acid to maintain a low pH (∼3.8–4.5), creating an environment that is hostile to the overgrowth of pathogens.[17] Probiotics are used to help restore and maintain this protective ecosystem.

• Bacterial Vaginosis (BV) and Vulvovaginal Candidiasis (Yeast Infections): Evidence suggests that oral or intravaginal administration of specific probiotic strains can be effective in treating acute episodes of BV and yeast infections (often as an adjunct to standard antimicrobials) and, perhaps more importantly, in reducing the high rates of recurrence.[17] The primary goal is to re-establish a stable, [Lactobacillus]-dominant microbiome.
• Key Strains: The scientific evidence points strongly to the superiority of [Lactobacillus crispatus] as the premier species for maintaining vaginal health and preventing BV recurrence.[17] Strains of [Lacticaseibacillus rhamnosus] (e.g., GR-1) and [Limosilactobacillus reuteri] (e.g., RC-14), often formulated together, also have supporting clinical evidence for their ability to colonize the vagina after oral administration and help restore a healthy microbial balance.[11] The paradox of [Lactobacillus iners], which is often the most abundant species detected but is associated with microbiome instability and dysbiosis, further underscores that not all lactobacilli are equally protective in the vaginal environment.[21]

4.3 Dermatological Conditions: Atopic Dermatitis (Eczema)

The evidence for using [Lactobacillus] to treat existing eczema is notably mixed, inconsistent, and largely inconclusive, especially for adult populations.[45] While the "gut-skin axis" provides a plausible biological rationale, clinical trial results have been disappointing.

• Key Findings: Multiple large meta-analyses and a Cochrane review have found no consistent, significant benefit of [Lactobacillus] supplementation on eczema symptoms, as measured by the SCORAD (SCORing Atopic Dermatitis) index.[45] However, some subgroup analyses have identified potential signals for efficacy under very specific circumstances. The effect appears highly dependent on the strain used ( [Limosilactobacillus fermentum] and [Lactobacillus salivarius] have shown the most promise in some analyses), the age of the patient (stronger signal in children under one year), the duration of treatment (longer treatment of ≥12 weeks seems better), and the baseline severity of the disease (greater effect in moderate-to-severe AD).[14] The evidence for preventing the development of eczema through maternal or infant supplementation is also conflicting and not consistently proven.[43] Overall, the current body of evidence does not support a general recommendation for probiotics in the routine treatment of eczema.

4.4 Metabolic Health

This is a rapidly emerging and promising field of research, investigating the link between gut microbiota modulation and systemic metabolic outcomes like obesity, type 2 diabetes, and liver disease.[20]

• Mechanisms: [Lactobacillus] strains are thought to improve metabolic health through several interconnected pathways: enhancing gut barrier function to reduce the translocation of inflammatory bacterial components (like LPS), which contributes to low-grade systemic inflammation; producing SCFAs that influence appetite-regulating hormones like GLP-1 and PYY; and directly modulating host cholesterol and bile acid metabolism.[20]
• Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Preclinical models and early clinical trials suggest that certain [Lactobacillus] strains can attenuate the accumulation of fat in the liver (steatosis) by improving the gut barrier, reducing inflammation, and favorably modulating bile acid profiles.[28]
• Weight Management and Cholesterol: Specific strains, such as [Lactobacillus gasseri] SBT2055, have been linked in some human trials to modest reductions in body weight and visceral fat.[20] Additionally, strains with high bile salt hydrolase (BSH) activity, including certain [L. reuteri] and [L. plantarum] strains, can lower serum cholesterol by breaking down bile acids in the gut. This disruption of bile acid recycling prompts the liver to pull more cholesterol from the bloodstream to synthesize new bile acids.[7]

The differential efficacy across these conditions is telling. Probiotics demonstrate their strongest effects in conditions characterized by acute dysbiosis, where the microbial ecosystem has been clearly damaged (e.g., by antibiotics) or disrupted by a specific pathogen overgrowth (e.g., BV). Their role is one of ecological restoration. In contrast, their efficacy is weaker in chronic, multifactorial diseases like eczema or metabolic syndrome, where the dysbiosis is more complex and intertwined with host genetics and lifestyle factors. This suggests that current probiotics are more effective as "restoration agents" than as "modulators" of complex, chronic pathophysiology.

---

Table 4.1: Clinical Evidence Summary for Lactobacillus Probiotics

Clinical Indication	Specific Strain(s) with Strongest Evidence	Typical Effective Dosage Range (CFU/day)	Level of Evidence	Key Findings / Comments
Antibiotic-Associated Diarrhea (Prevention)	Lacticaseibacillus rhamnosus GG (LGG), Lacticaseibacillus casei DN114001, Multi-strain formulas (e.g., with L. acidophilus) 9	5–40 billion	Strong	Reduces risk by 30-50%. Must be co-administered with antibiotics (separated by ≥2 hrs). Higher doses are more effective.
Irritable Bowel Syndrome (IBS)	Multi-strain: VSL#3/Visbiome, Symprove. Single-strain: Lactiplantibacillus plantarum 299v 10	10 billion – 900 billion (VSL#3)	Moderate	Improves global symptoms, especially bloating and pain. Benefit requires weeks to manifest and may cease upon discontinuation.
H. pylori Infection (Adjunct)	L. acidophilus, L. casei, L. reuteri 7	5–20 billion	Moderate	Used with standard antibiotic therapy. Increases eradication rates and reduces side effects of treatment. Not a standalone therapy.
Bacterial Vaginosis (BV) (Treatment/Prevention)	Lactobacillus crispatus (esp. for prevention), Lacticaseibacillus rhamnosus GR-1, Limosilactobacillus reuteri RC-14 11	1–10 billion (oral or vaginal)	Moderate	Helps restore a healthy, acidic vaginal microbiome. Most effective for preventing recurrence. L. crispatus is considered the optimal protective species.
Atopic Dermatitis (Eczema) (Treatment)	Limosilactobacillus fermentum, Lactobacillus salivarius (some positive signals) 14	10–20 billion	Inconclusive / Conflicting	Overall evidence does not support routine use. Any potential benefit is highly dependent on strain, age (better in infants), and disease severity.
Metabolic Health (Cholesterol, MASLD)	L. reuteri, L. plantarum (BSH-active strains for cholesterol), L. gasseri (weight) 7	10–20 billion	Preliminary / Emerging	Promising preclinical data and early human trials. Mechanisms involve bile acid modulation and gut barrier improvement. Not yet standard of care.

---

Section 5: In-Depth Profile of Archetypal Strains

This section provides a detailed molecular and mechanistic profile of three of the most heavily researched and commercially significant [Lactobacillus] strains. These examples serve to illustrate the principles of strain specificity and the multifaceted mechanisms of action in concrete terms.

5.1 Lacticaseibacillus rhamnosus GG (LGG) (ATCC 53103)

• Overview: LGG is one of the world's most extensively studied and documented probiotic strains. Originally isolated in 1983 from the intestinal tract of a healthy human, it was selected for its exceptional resilience, demonstrating high tolerance to acid and bile and a remarkable capacity for adhering to intestinal cells.[3]
• Key Mechanisms & Molecular Effectors: The robustness of LGG stems from a synergistic combination of multiple mechanisms [22]:
• Pili (SpaCBA): LGG is covered in fimbria-like appendages known as pili. These structures, particularly the SpaC pilin protein, are essential for its ability to bind strongly to intestinal mucus and epithelial cells, form protective biofilms, and competitively exclude pathogens from adhesion sites.[1]
• Secreted Proteins (p40 and p75): LGG actively secretes two key proteins, p40 and p75, which function as critical signaling molecules. These proteins do not act directly on host cells but rather activate the host's Epidermal Growth Factor Receptor (EGFR) signaling pathway. This activation, in turn, promotes epithelial cell survival, strengthens tight junction integrity (reducing intestinal permeability), and dampens inflammatory responses. This represents a sophisticated, direct protein-mediated dialogue between the bacterium and its host.[22]
• Exopolysaccharides (EPS): The cell surface of LGG is coated in a layer of EPS, which acts as a physical shield, protecting the bacterium from antimicrobial peptides in the gut. The physical properties of this EPS layer are dynamic; it becomes more compact in acidic conditions (like the stomach) and looser in the presence of bile salts (in the intestine), a mechanism that modulates the accessibility of the adhesive pili.[22]
• Aflatoxin Binding: A unique property of LGG is its ability to physically bind and sequester dietary aflatoxins (potent carcinogens produced by molds), thereby reducing their absorption from the intestine.[51]
• Primary Clinical Evidence: LGG possesses some of the strongest clinical evidence among all probiotics, particularly for the prevention of AAD in children and the treatment of acute infectious gastroenteritis.[36] Its evidence for treating eczema is notably conflicting and varies by population.[49]

5.2 Lactobacillus acidophilus (e.g., NCFM, DDS-1, LA-05)

• Overview: [L. acidophilus] is a quintessential probiotic and a natural inhabitant of the human mouth, intestine, and vagina.[43] As an obligate homofermenter, it is a highly efficient producer of lactic acid, a key trait for its role in acidifying its environment.[1]
• Key Mechanisms & Molecular Effectors: Different strains of [L. acidophilus] exhibit distinct beneficial functions [8]:
• Lactose Digestion: Strains such as NCFM and DDS-1 possess high levels of the enzyme lactase (β-galactosidase). This allows them to effectively break down lactose as they transit through the GI tract, providing a direct mechanism for alleviating the symptoms of lactose intolerance (bloating, cramps, diarrhea) in individuals with lactase deficiency.[8]
• Cholesterol Metabolism: Multiple [L. acidophilus] strains (e.g., NCFM, ATCC 4356) have been demonstrated to lower serum cholesterol levels. They employ several mechanisms, including the direct assimilation of cholesterol into their cell membranes, the inhibition of dietary cholesterol absorption in the intestine (by downregulating the host gene NPC1L1), and the modulation of bile acid metabolism.[7]
• Immunomodulation and Pain Signaling: The surface layer (S-layer) proteins of the NCFM strain are crucial for its interaction with the host immune system and its anti-inflammatory effects. Strain PTCC 1643 has been shown to modulate the expression of TLR2 and TLR4 on intestinal cells.[8] Remarkably, [L. acidophilus] can also directly influence visceral pain perception by upregulating μ-opioid and cannabinoid receptors in the colonic epithelium.[27]
• Primary Clinical Evidence: [L. acidophilus] has good evidence for improving symptoms of lactose intolerance, serving as an effective adjunct in [H. pylori] eradication therapy, and as a key component of multi-strain formulations for IBS and vaginal health.[8]

5.3 Limosilactobacillus reuteri (e.g., DSM 17938, ATCC 55730, RC-14)

• Overview: [L. reuteri] is considered a true autochthonous member of the human microbiota, found colonizing the GI tract from infancy (via breast milk) into adulthood.[19] It is an obligate heterofermenter with a remarkably diverse and strain-specific range of functions.[1]
• Key Mechanisms & Molecular Effectors: [L. reuteri] strains possess some of the most specialized and potent mechanisms known among probiotics [13]:
• Antimicrobial Production (Reuterin): The signature ability of many (but not all) [L. reuteri] strains is the production of reuterin, a potent, broad-spectrum antimicrobial substance derived from glycerol. This gives these strains a powerful competitive advantage against a wide range of pathogens.[12] It is critical to note this is a strain-specific trait; for example, the well-studied probiotic strain RC-14 does not produce reuterin, relying on other mechanisms for its effects.[12]
• Immunomodulation via Histamine: In a unique anti-inflammatory mechanism, certain [L. reuteri] strains (e.g., ATCC 6475) can metabolize the amino acid L-histidine into histamine. This bacterially-produced histamine then acts on H2 receptors on host immune cells to suppress the production of the pro-inflammatory cytokine TNF-α.[24]
• Gut Barrier and Mucin Production: Strains of [L. reuteri] enhance the expression of key mucin genes (MUC2, MUC13), contributing to a thicker, more protective intestinal mucus layer.[26]
• Regulatory T Cell (Treg) Promotion: [L. reuteri] has been shown to promote the development and function of Tregs, a specialized subset of T cells that are critical for maintaining immune tolerance and preventing autoimmune and inflammatory responses.[24]
• Primary Clinical Evidence: [L. reuteri] has strong clinical evidence for specific indications. Strain DSM 17938 is highly effective for treating infantile colic and functional abdominal pain in children.[13] Strain RC-14, typically combined with [L. rhamnosus] GR-1, is well-supported for use in restoring vaginal health.[11]

The existence of highly specialized functions, such as the production of reuterin or immunomodulatory histamine, demonstrates that certain probiotic strains have evolved sophisticated molecular tools to actively and precisely modulate their host's environment and physiology. This positions these specific strains less as simple "good bacteria" and more as targeted, biological response modifiers.

Section 6: Safety, Administration, and Regulatory Considerations

This section addresses the critical practical aspects of using [Lactobacillus] as a therapeutic agent, covering its general safety profile, potential drug interactions, and the complex and often misunderstood regulatory landscape that governs its sale and use.

6.1 Safety Profile, Side Effects, and Contraindications

• General Safety: For the general healthy population, [Lactobacillus] probiotics are designated as "Generally Regarded As Safe" (GRAS) by U.S. regulatory bodies. This status is supported by their long history of safe consumption in fermented foods and widespread use as dietary supplements.[23]
• Common Side Effects: The most frequently reported side effects are mild, transient, and gastrointestinal in nature. These include increased gas (flatulence) and bloating, which typically occur upon initiating supplementation as the gut microbiota adapts to the new organism. These symptoms usually resolve with continued use.[41]
• Serious Risks and Contraindications: The safety profile of [Lactobacillus] is highly conditional and changes dramatically in vulnerable populations. While extremely rare in healthy individuals, serious systemic infections such as bacteremia (bacteria in the bloodstream) and endocarditis (infection of the heart lining) have been reported. Therefore, the use of live probiotics is contraindicated or requires extreme caution and strict medical supervision in the following high-risk groups [6]:
• Severely Immunocompromised Patients: This includes individuals with advanced HIV/AIDS, patients undergoing chemotherapy or radiation, and those on high-dose immunosuppressive medications (e.g., after organ transplant).
• Critically Ill Patients: Particularly those in an Intensive Care Unit (ICU) setting.
• Patients with Central Venous Catheters: The presence of indwelling lines increases the risk of contamination and subsequent line-associated sepsis.
• Patients with a Compromised Gut Barrier: Conditions such as severe acute pancreatitis, short bowel syndrome, or a known gastrointestinal wall perforation significantly increase the risk of bacterial translocation from the gut into the bloodstream.
• Patients with Damaged or Prosthetic Heart Valves: These individuals are at a higher risk of developing endocarditis.

6.2 Drug Interactions

Potential interactions with conventional medications must be considered:

• Antibiotics: This is the most common and significant interaction. The co-administration of antibiotics will kill live probiotic bacteria, rendering them ineffective. To mitigate this, it is standard clinical practice to separate the administration of the probiotic and the antibiotic by at least two hours.[38] To aid in the restoration of the microbiota after the antibiotic-induced disruption, it is often recommended to continue the probiotic for several days to weeks after the antibiotic course is completed.[39]
• Immunosuppressants: The concurrent use of probiotics with immunosuppressive drugs (e.g., cyclosporine, tacrolimus, corticosteroids) is a significant concern. In a host with a weakened immune system, the probiotic itself could theoretically act as an opportunistic pathogen and cause a systemic infection.[38] This combination requires a careful risk-benefit analysis by a qualified healthcare professional.
• Antifungals: These medications primarily affect yeast-based probiotics like [S. boulardii] and are not expected to interact significantly with bacterial probiotics like [Lactobacillus].[38]

6.3 Dosing, Formulation, and Regulatory Status

• Formulations: [Lactobacillus] probiotics are commercially available in a wide variety of formulations, including lyophilized (freeze-dried) powders in capsules or sachets, liquid suspensions, and as active cultures in fermented dairy and non-dairy foods like yogurt, kefir, and certain beverages.[7]
• Dosing: Probiotic doses are quantified in Colony-Forming Units (CFUs), which represent the number of viable, live bacteria in a serving. Clinically effective doses vary substantially depending on the specific strain and the intended therapeutic indication, but they typically fall within the range of 1 billion to 50 billion CFUs per day.[35] For well-studied indications like AAD prevention in children, doses of 5 to 40 billion CFU/day are common.[36]
• Regulatory Landscape (U.S. Focus): This is a critical and often misunderstood area. In the United States, the vast majority of probiotic products are regulated as dietary supplements, not as drugs.[58] This distinction has profound implications:
• Under the Dietary Supplement Health and Education Act of 1994 (DSHEA), dietary supplements do not require pre-market approval from the Food and Drug Administration (FDA) to demonstrate safety or efficacy.[58]
• The responsibility for ensuring product safety and substantiating any health claims rests with the manufacturer. The evidentiary burden is significantly lower than that required for a pharmaceutical drug, and the FDA's role is primarily one of post-market surveillance (i.e., acting after a problem has been identified).[58]

This regulatory framework creates a significant "efficacy gap" between the promising results seen in highly controlled clinical trials (which use a specific, quality-controlled, and verified strain) and the reality of the consumer marketplace. A positive trial for strain "X" does not guarantee that a consumer purchasing a product labeled "Strain X" is actually receiving a viable, correctly identified, or effective dose. This lack of standardization and enforcement means that product quality, purity, and CFU count can vary widely and may not match label claims. This gap is arguably the single greatest barrier to the reliable and widespread clinical application of probiotics, placing an enormous burden on clinicians and consumers to vet manufacturers and product quality.

Section 7: Future Directions and Emerging Research

The field of probiotic science is rapidly evolving beyond its traditional focus on gut health. Cutting-edge research is now exploring the influence of [Lactobacillus] on systemic health, including mental well-being and reproductive outcomes, paving the way for more personalized and targeted therapeutic applications.

7.1 The Gut-Brain Axis: Probiotics for Mental Health

A burgeoning area of research is the investigation of the "gut-brain axis," a complex bidirectional communication network linking the gut microbiota with the central nervous system.[32] This research is repositioning probiotics from simple "digestive aids" to potential modulators of mood and behavior.

• Mechanisms: [Lactobacillus] strains are hypothesized to influence brain function and mental health through several pathways:
• Neuroactive Molecule Production: Certain strains can produce neuroactive compounds directly within the gut, such as GABA (an inhibitory neurotransmitter) and precursors to serotonin.[30]
• Inflammation Modulation: By reducing systemic inflammation, which is increasingly linked to the pathophysiology of depression and anxiety, probiotics may indirectly improve mental health outcomes.[32]
• Vagus Nerve Stimulation: The gut microbiota can communicate with the brain via the vagus nerve, a major neural highway.
• Neurotrophic Factor Support: Animal studies have shown that probiotic administration can increase levels of brain-derived neurotrophic factor (BDNF) in the brain, a key molecule for supporting neuronal health, growth, and plasticity.[34]
• Key Findings: While still in its early stages, the evidence is compelling. Preclinical studies have shown that early-life colonization with LGG can lead to lasting reductions in anxiety-like behavior in adult animal models.[34] Some preliminary human studies using specific multi-strain probiotics have reported modest improvements in mood, anger, and fatigue.[11] However, this field requires significantly more rigorous, large-scale human trial data before any clinical recommendations can be made.

7.2 Towards Personalized Probiotic Therapy

The future of probiotic medicine lies in moving away from a generic, one-size-fits-all approach and towards personalized interventions that are tailored to an individual's unique microbiome, genetics, and health status.[18]

• Integration with Nutrition and Lifestyle: Emerging research highlights that the efficacy of a probiotic can be significantly enhanced when combined with other interventions. A recent study on women with unhealthy lifestyles undergoing in-vitro fertilization (IVF) found that a personalized nutrition program combined with the administration of [Lactobacillus crispatus] M247 significantly improved live birth rates compared to a control group.[18] This demonstrates the power of treating the microbiome not in isolation, but as a key variable within the host's broader physiological system.
• Synbiotics: The strategic combination of a probiotic (a live beneficial organism) with a prebiotic (a specific, non-digestible fiber that serves as food for that organism) is known as a synbiotic. This approach is designed to improve the survival, implantation, and activity of the probiotic strain in the gut, thereby enhancing its efficacy.[32] Future strategies will likely involve the precise pairing of specific prebiotics with specific probiotic strains to maximize therapeutic benefit.

7.3 Concluding Remarks and Recommendations for Future Research

[Lactobacillus] represents a genus of microorganisms with significant and proven therapeutic potential. However, its clinical utility is fundamentally governed by the principles of strain-, disease-, and dose-specificity. The body of evidence is robust and compelling for a select few indications, such as the prevention of antibiotic-associated diarrhea, but remains preliminary, conflicting, or inconclusive for many others. The inconsistent quality and lack of stringent regulatory oversight for products marketed as dietary supplements remain major hurdles to translating promising research into reliable clinical outcomes.

The ultimate trajectory of this field is likely a move away from the simple term "probiotic" and towards a new paradigm of "microbiota-targeted therapeutics." This will involve a sophisticated toolkit that includes not just live bacteria, but also personalized synbiotics, next-generation strains genetically engineered for specific functions, and postbiotics (purified bacterial components) to precisely and safely modulate host physiology. This evolution represents the maturation of probiotic science from a supplement-based industry into a legitimate branch of precision medicine.

To accelerate this transition, future research must prioritize:

• Large-scale, long-term, and methodologically rigorous RCTs that adhere to strict reporting standards.
• Direct, head-to-head trials comparing the efficacy of different strains for the same clinical indication.
• Mechanistic studies designed to elucidate the precise molecular interactions between probiotic strains and the host.
• Universal adoption of the updated taxonomic nomenclature to ensure clarity and consistency across the literature.
• The identification and validation of biomarkers that can predict which individuals are most likely to respond to a specific probiotic intervention, enabling a truly personalized approach.

Works cited

1. Lactobacillus spp. for Gastrointestinal Health: Current and Future ..., accessed August 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9019120/
2. Lactobacillus - Wikipedia, accessed August 12, 2025, https://en.wikipedia.org/wiki/Lactobacillus
3. Lactobacillus Species: Taxonomic Complexity and Controversial Susceptibilities | Clinical Infectious Diseases | Oxford Academic, accessed August 12, 2025, https://academic.oup.com/cid/article/60/suppl_2/S98/379146
4. Metabolism Characteristics of Lactic Acid Bacteria and the Expanding Applications in Food Industry - Frontiers, accessed August 12, 2025, https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2021.612285/full
5. Strain-Specific Therapeutic Potential of Lactiplantibacillus plantarum ..., accessed August 12, 2025, https://www.mdpi.com/2072-6643/17/7/1165
6. Lactobacillus Bacteremia and Probiotics: A Review - MDPI, accessed August 12, 2025, https://www.mdpi.com/2076-2607/11/4/896
7. Health-Promoting Effects of Lactobacillus acidophilus and Its Technological Applications in Fermented Food Products and Beverages - MDPI, accessed August 12, 2025, https://www.mdpi.com/2311-5637/10/8/380
8. The Functional Roles of Lactobacillus acidophilus in Different ..., accessed August 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9668099/
9. Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis - PubMed, accessed August 12, 2025, https://pubmed.ncbi.nlm.nih.gov/29868585/
10. The Importance of Strain - Probiotic Advisor, accessed August 12, 2025, https://www.probioticadvisor.com/probiotic-essentials-1/the-importance-of-strain/
11. Lactobacillus rhamnosus: Strain-Specific Benefits Backed by Science - Seed, accessed August 12, 2025, https://seed.com/cultured/lactobacillus-rhamnosus-benefits-strains-science-guide/
12. Evaluation of Reuterin Production in Urogenital Probiotic ..., accessed August 12, 2025, https://journals.asm.org/doi/10.1128/aem.00139-08
13. The role of potential probiotic strains Lactobacillus reuteri in various intestinal diseases: New roles for an old player, accessed August 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9932687/
14. Single-Strain Probiotic Lactobacilli for the Treatment of Atopic ..., accessed August 12, 2025, https://www.mdpi.com/1999-4923/15/4/1256
15. Single-Strain Probiotic Lactobacilli for the Treatment of Atopic Dermatitis in Children: A Systematic Review and Meta-Analysis - PubMed, accessed August 12, 2025, https://pubmed.ncbi.nlm.nih.gov/37111741/
16. Probiotics for the treatment of atopic dermatitis in adults - Study Summary - Examine.com, accessed August 12, 2025, https://examine.com/research-feed/study/1rEO6d/
17. Do You Need Probiotics for Your Vagina? - WebMD, accessed August 12, 2025, https://www.webmd.com/women/vaginal-probiotics
18. O-302 Impact of personalized nutrition and Lactobacillus crispatus ..., accessed August 12, 2025, https://academic.oup.com/humrep/article-abstract/doi/10.1093/humrep/deaf097.302/8171262
19. The Lactobacillus and Bifidobacterium microflora of the human intestine: Composition and succession - ResearchGate, accessed August 12, 2025, https://www.researchgate.net/publication/11634866_The_Lactobacillus_and_Bifidobacterium_microflora_of_the_human_intestine_Composition_and_succession
20. The Role of Probiotics in Modulating Gut Microbiota and Metabolic ..., accessed August 12, 2025, https://www.mdpi.com/2813-9054/70/1/5
21. Contribution of Lactobacillus iners to Vaginal Health and Diseases: A Systematic Review, accessed August 12, 2025, https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2021.792787/full
22. Molecular Mechanisms of Lacticaseibacillus rhamnosus, LGG ..., accessed August 12, 2025, https://www.mdpi.com/2076-2607/12/4/794
23. Taxonomic and Strain-Specific Identification of the Probiotic Strain Lactobacillus rhamnosus 35 within the Lactobacillus casei Group | Applied and Environmental Microbiology - ASM Journals, accessed August 12, 2025, https://journals.asm.org/doi/10.1128/aem.02286-07
24. Role of Lactobacillus reuteri in Human Health and Diseases - PMC, accessed August 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5917019/
25. Mechanism of Lactobacillus reuteri Probiotic in Increasing Intestinal Mucosal Immune System, accessed August 12, 2025, https://oamjms.eu/index.php/mjms/article/download/7447/6615/65794
26. Limosilactobacillus reuteri Regulating Intestinal Function: A Review - MDPI, accessed August 12, 2025, https://www.mdpi.com/2311-5637/9/1/19
27. Treating irritable bowel syndrome with probiotics: the evidence | Proceedings of the Nutrition Society | Cambridge Core, accessed August 12, 2025, https://www.cambridge.org/core/journals/proceedings-of-the-nutrition-society/article/treating-irritable-bowel-syndrome-with-probiotics-the-evidence/2FEA1CD355F8C535F38B262C10D4B12B
28. Lactobacillus sp. for the Attenuation of Metabolic Dysfunction ... - MDPI, accessed August 12, 2025, https://www.mdpi.com/2076-2607/12/12/2488
29. Lactobacillus for the treatment and prevention of atopic dermatitis: Clinical and experimental evidence - PMC, accessed August 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9978199/
30. The metabolites of lactic acid bacteria: classification, biosynthesis and modulation of gut microbiota - Microbial Cell, accessed August 12, 2025, https://microbialcell.com/researcharticles/2023a-tang-microbial-cell/
31. Probiotics for the prevention of antibiotic-associated diarrhoea: a systematic review and meta-analysis | BMJ Open, accessed August 12, 2025, https://bmjopen.bmj.com/content/11/8/e043054
32. A comprehensive review of probiotics and human health-current prospective and applications - Frontiers, accessed August 12, 2025, https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2024.1487641/full
33. Lactobacillus reuteri DSM 17938: Review of Evidence in Functional Gastrointestinal Disorders - Longdom Publishing, accessed August 12, 2025, https://www.longdom.org/open-access/emlactobacillus-reuteriem-dsm-17938-review-of-evidence-in-functional-gastrointestinal-disorders-41973.html
34. Lactobacillus rhamnosus GG colonization in early life regulates gut ..., accessed August 12, 2025, https://www.researchgate.net/publication/357947432_Lactobacillus_rhamnosus_GG_colonization_in_early_life_regulates_gut-brain_axis_and_relieves_anxiety-like_behavior_in_adulthood
35. Role of Lactobacillus in the prevention of antibiotic-associated ..., accessed August 12, 2025, https://www.ncbi.nlm.nih.gov/books/NBK80631/
36. Feature Review: Probiotics for the prevention antibiotic-associated diarrhea in children, accessed August 12, 2025, https://www.cochrane.org/about-us/news/feature-review-probiotics-prevention-antibiotic-associated-diarrhea-children
37. What is the recommended dose of Lactobacillus (Probiotic) in pediatric patients?, accessed August 12, 2025, https://www.droracle.ai/articles/12749/lactobacillus-dose-in-pediatric-
38. Probiotics - Page 13 - Medscape, accessed August 12, 2025, https://www.medscape.com/viewarticle/719654_13
39. Indication-specific dosing for Lactobacillus acidophilus, Bacid ..., accessed August 12, 2025, https://reference.medscape.com/drug/bacid-culturelle-lactobacillus-344525
40. Best Probiotics For Irritable Bowel Syndrome (IBS) Explained | Diet ..., accessed August 12, 2025, https://www.dietvsdisease.org/probiotics-ibs/
41. LACTOBACILLUS ACIDOPHILUS: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews - WebMD, accessed August 12, 2025, https://www.webmd.com/vitamins/ai/ingredientmono-790/lactobacillus-acidophilus
42. Lactobacillus: Uses and Risks - WebMD, accessed August 12, 2025, https://www.webmd.com/vitamins-and-supplements/lactobacillus-uses-and-risks
43. Acidophilus - Mayo Clinic, accessed August 12, 2025, https://www.mayoclinic.org/drugs-supplements-acidophilus/art-20361967
44. Acidophilus (Lactobacillus Acidophilus): Uses, Benefits & Side Effects - Cleveland Clinic, accessed August 12, 2025, https://my.clevelandclinic.org/health/drugs/22650-acidophilus
45. Can Probiotics Help With Eczema? What the Science Says ..., accessed August 12, 2025, https://www.myeczemateam.com/resources/probiotics-for-eczema-effectiveness-benefits-and-uses
46. The impact of prebiotics, probiotics and synbiotics on the prevention and treatment of atopic dermatitis in children: an umbrella meta-analysis - Frontiers, accessed August 12, 2025, https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2025.1498965/full
47. Probiotics to Reduce the Severity of Atopic Dermatitis in Pediatric Patients: A Systematic Review and Meta-Analysis | Actas Dermo-Sifiliográficas, accessed August 12, 2025, https://www.actasdermo.org/en-probiotics-reduce-severity-atopic-dermatitis-articulo-S1578219021002973
48. Effects of probiotic supplementation in adult with atopic dermatitis: a systematic review with meta-analysis | Clinical and Experimental Dermatology | Oxford Academic, accessed August 12, 2025, https://academic.oup.com/ced/article/49/1/46/7273557
49. The Effectiveness of Probiotic Lactobacillus rhamnosus and Lactobacillus casei Strains in Children with Atopic Dermatitis and Cow's Milk Protein Allergy: A Multicenter, Randomized, Double Blind, Placebo Controlled Study - MDPI, accessed August 12, 2025, https://www.mdpi.com/2072-6643/13/4/1169
50. Potential benefits of Lactobacillus plantarum as probiotic and its advantages in human health and industrial applications: A review - ResearchGate, accessed August 12, 2025, https://www.researchgate.net/publication/323918051_Potential_benefits_of_Lactobacillus_plantarum_as_probiotic_and_its_advantages_in_human_health_and_industrial_applications_A_review
51. www.frontiersin.org, accessed August 12, 2025, https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2018.01501/full#:~:text=The%20mechanism%20reported%20included%20binding,et%20al.%2C%202006)..&sa=D&source=editors&ust=1754996562869875&usg=AOvVaw1GId1DwXkESBT6K5_My1Y5)
52. Lactobacillus reuteri in digestive system diseases: focus on clinical trials and mechanisms, accessed August 12, 2025, https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2023.1254198/full
53. Safety of Probiotics | Clinical Infectious Diseases | Oxford Academic, accessed August 12, 2025, https://academic.oup.com/cid/article/46/Supplement_2/S104/276784
54. Probiotics: What They Are, Benefits & Side Effects - Cleveland Clinic, accessed August 12, 2025, https://my.clevelandclinic.org/health/treatments/14598-probiotics
55. Lactobacillus acidophilus (oral route) - Side effects & dosage - Mayo Clinic, accessed August 12, 2025, https://www.mayoclinic.org/drugs-supplements/lactobacillus-acidophilus-oral-route/description/drg-20310912
56. What are the contraindications for Lactobacillus (probiotic) supplementation? - Dr.Oracle, accessed August 12, 2025, https://www.droracle.ai/articles/49941/contraindications-for-lactobacillus
57. Lactobacillus acidophilus Disease Interactions - Drugs.com, accessed August 12, 2025, https://www.drugs.com/disease-interactions/lactobacillus-acidophilus.html
58. Regulatory Oversight and Safety of Probiotic Use - PMC, accessed August 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3294522/
59. US Food and Drug Administration and Probiotics: Regulatory Categorization | Clinical Infectious Diseases | Oxford Academic, accessed August 12, 2025, https://academic.oup.com/cid/article-abstract/46/Supplement_2/S133/277296
60. Metabolomic Analysis of Lactobacillus acidophilus, L. gasseri, L. crispatus, and Lacticaseibacillus rhamnosus Strains in the Presence of Pomegranate Extract - Frontiers, accessed August 12, 2025, https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2022.863228/full